Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P51857: Variant p.Pro133Arg

Aldo-keto reductase family 1 member D1
Gene: AKR1D1
Feedback?
Variant information Variant position: help 133 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Proline (P) to Arginine (R) at position 133 (P133R, p.Pro133Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (P) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CBAS2; highly reduced KM and Vmax with cortisone as substrate. Increases KM and decreases kcat with testosterone as substrate. No change in NADPH affinity. More thermolabile in the absence of NADPH. Reduces 5-beta-reductase activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 133 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 326 The length of the canonical sequence.
Location on the sequence: help YVDLYIIEVPMAFKPGDEIY P RDENGKWLYHKSNLCATWEA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         YVDLYIIEVPMAFKPGDEIYPRDENGKWLYHKSNLCATWEA

Mouse                         YIDLYIIELPMAFKPGKEIYPRDENGRIIYDKTNLCATWEA

Rat                           YIDLYIIEMPMAFKPGEEFYPKDENGRVIYHKSNLCATWEA

Rabbit                        YIDLYIIEIPMAFKPGDVVYPRDENGKWLYHKTNLCATWEA
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 326 Aldo-keto reductase family 1 member D1
Binding site 120 – 120
Binding site 132 – 132
Mutagenesis 120 – 120 E -> A. Loss of activity.



Literature citations
Characterization of disease-related 5beta-reductase (AKR1D1) mutations reveals their potential to cause bile acid deficiency.
Drury J.E.; Mindnich R.; Penning T.M.;
J. Biol. Chem. 285:24529-24537(2010)
Cited for: CATALYTIC ACTIVITY; CHARACTERIZATION OF VARIANTS CBAS2 PHE-106; ARG-133; LEU-198; GLU-223 AND CYS-261; BIOPHYSICOCHEMICAL PROPERTIES; SRD5B1 (AKR1D1) gene analysis in delta(4)-3-oxosteroid 5beta-reductase deficiency: evidence for primary genetic defect.
Gonzales E.; Cresteil D.; Baussan C.; Dabadie A.; Gerhardt M.F.; Jacquemin E.;
J. Hepatol. 40:716-718(2004)
Cited for: VARIANTS CBAS2 ARG-133 AND CYS-261;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.